Crinetics Pharmaceuticals
CRNX
CRNX was delisted on the 31st of August, 2026.
128 hedge funds and large institutions have $884M invested in Crinetics Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 59 increasing their positions, 28 reducing their positions, and 13 closing their positions.
23,500% more call options, than puts
Call options by funds: $472K | Put options by funds: $2K
111% more repeat investments, than reductions
Existing positions increased: 59 | Existing positions reduced: 28
54% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 13
5% more funds holding
Funds holding: 122 → 128 (+6)
1.04% more ownership
Funds ownership: 101.1% → 102.14% (+1%)
11% less capital invested
Capital invested by funds: $995M → $884M (-$111M)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$17.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$15.4M |
| 3 |
O
OrbiMed
New York
|
+$14M |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$9.94M |
| 5 |
Morgan Stanley
New York
|
+$9.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$26.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$19.2M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.8M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$10.9M |
CRNX Hedge Fund Activity: Q1 2023 in Review
128 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Crinetics Pharmaceuticals (CRNX) for Q1 2023, worth a combined $884M — down 11% from $995M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new CRNX positions and 13 closed out — a net gain of 7 holders — while 59 added to existing stakes and 28 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $17.2M. The largest seller was Braidwell, cutting an estimated $26.8M.
- 128 institutional investors held Crinetics Pharmaceuticals (CRNX) as of Q1 2023, up from 122 in Q4 2022.
- Funds reported $884M of Crinetics Pharmaceuticals stock for Q1 2023, down 11% quarter-over-quarter.
- 20 funds opened new Crinetics Pharmaceuticals positions in Q1 2023 and 13 closed out, a net change of +7 holders.
- The largest Crinetics Pharmaceuticals buyer in Q1 2023 was T. Rowe Price Investment Management, an estimated $17.2M added.
- The largest Crinetics Pharmaceuticals seller in Q1 2023 was Braidwell, an estimated $26.8M sold.
Based on aggregated 13F filings for Q1 2023.